[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Puerto Rico\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":277},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,48,78,118,141,165,187,213,239,258],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100636866","phase-4-impact-of-preemptive-analgesia-on-postoperative-pain-in-orthognathic-surgery-100636866",false,"NCT07571252","Impact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery","Impact of Preemptive Analgesia on Postoperative Pain in Patients Undergoing Orthognathic Surgery: A Randomized Controlled Trial.","Inclusion Criteria:\n\n* Adults aged 21 to 65 years.\n* American Society of Anesthesiologists (ASA) physical status I or II.\n* Scheduled to undergo orthognathic surgery including bilateral sagittal split osteotomy and Le Fort I osteotomy under general anesthesia.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding.\n* Known allergy or intolerance to acetaminophen, ibuprofen, or other nonsteroidal anti-inflammatory drugs (NSAIDs).\n* Renal dysfunction, defined as estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m².\n* Hepatic dysfunction, defined as liver enzyme levels greater than twice the upper limit of normal.\n* History of bleeding disorders or coagulopathy.\n* Active or recent peptic ulcer disease.\n* Current use of recreational drugs, including cannabis, that in the judgment of the investigators could interfere with anesthesia management, postoperative pain assessment, or study outcomes.\n* Any medical condition that, in the judgment of the investigators, would make participation unsafe or interfere with study participation.","ALL","21 Years","65 Years",{"count":20,"type":21},72,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This randomized controlled clinical trial evaluates the effect of preemptive analgesia on postoperative pain outcomes in adult patients undergoing orthognathic surgery. Participants scheduled for bilateral sagittal split osteotomy and Le Fort I osteotomy under general anesthesia will be randomized to one of three groups: intravenous acetaminophen, intravenous ibuprofen, or a control group receiving standard postoperative analgesia without preoperative medication.\n\nThe study aims to determine whether the administration of pre-surgical analgesics reduces postoperative pain intensity and analgesic requirements during the early postoperative period. Pain will be assessed using a standardized pain scale at multiple time points following surgery, and secondary outcomes will include postoperative analgesic consumption and patient satisfaction with pain control.\n\nThis investigation seeks to contribute evidence supporting multimodal analgesic strategies and improved postoperative pain management in patients undergoing orthognathic surgery.",[27,28],"Post Operative Pain","Orthognathic Surgery",[30,28,31,32,33,34],"Preemptive Analgesia","Postoperative Pain","Maxillofacial Surgery","Multimodal Analgesia","Randomized controlled trial","NOT_YET_RECRUITING","2026-04-29",{"date":38,"type":39},"2026-05-06","ACTUAL",{"date":41,"type":21},"2026-04",{"date":43,"type":21},"2027-02",{"name":45,"class":46},"University of Puerto Rico","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100548785","using-technology-to-improve-function-for-older-latinos-with-disabilities-in-underserved-areas-100548785","NCT06425510","Using Technology to Improve Function for Older Latinos With Disabilities in Underserved Areas","Tech Enabled Functional Health: Bridging Primary Care Gaps for Older Latinos With Functional Disabilities in Underserved Communities","Inclusion Criteria:\n\n* Spanish speaking Latino adults ≥65 years\n* With a physical function impairment (PROMIS-HAQ T-Score ≤45)\n* Living independently in the community (not requiring supervision to perform their daily living activities)\n* Self-reported ability to participate in a 6 weeks of group intervention\n* Having no plans to move for the next 12 months\n\nExclusion Criteria:\n\n* Currently residing in a nursing or group home\n* Receiving home healthcare services\n* Having a significant cognitive impairment as evidenced by a score ≤23 in the Mini Mental State Examination (MMSE)",{"count":56,"type":21},76,[58],"NA","This project aims to test a culturally appropriate assistive technology (AT) intervention called VIVE-AT to help older Latinos with disabilities improve their function and quality of life. The researchers will first refine the VIVE-AT program based on feedback from a Community Advisory Board and focus groups with older Latinos with disabilities. Then, 76 older Latinos with disabilities will be recruited from a primary care clinic serving low-income communities in Puerto Rico. They will be randomly assigned to either receive the VIVE-AT intervention in the primary care clinic or be placed on a waitlist with regular phone calls. All participants will continue to receive standard care at the clinic.",[61,62],"Aging","Disability Physical",[64,65,66,67,68,69],"self help devices","behavioral intervention","assistive technology","primary health care","community health workers","older Latinos","2026-04-10",{"date":72,"type":39},"2026-04-13",{"date":74,"type":21},"2026-08-01",{"date":76,"type":21},"2027-12-31",{"name":45,"class":46},{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},"100621321","phase-4-esketamine-with-or-without-integration-therapy-for-treatment-resistant-depression-100621321","NCT07369102","Esketamine With or Without Integration Therapy for Treatment-Resistant Depression","Esketamine With or Without Psychedelic Preparation and Integration for Treatment-Resistant Depression: A Randomized Controlled Trial","KIND-PR","Inclusion Criteria:\n\n* Age: Adults aged 21 to 65 years.\n* Diagnosis: Current Major Depressive Disorder (MDD) as confirmed by Structured Clinical Interview for DSM5 (SCID-5).\n* Treatment Resistance: Failure to achieve remission with at least two antidepressants of adequate dose and duration (TRD criteria) as confirmed by SCID-5.\n* Symptom Severity: Baseline Montgomery-Åsberg Depression Rating Scale (MADRS) ≥30.\n* Suicidal Ideation: Participants with baseline passive or active suicidal ideation may be included, provided they do not meet criteria for inpatient admission and are deemed clinically stable for outpatient care. This will be measured with the Columbia Suicide Severity Rating Scale (C-SSRS).\n* Consent: Ability to understand and voluntarily provide written informed consent.\n* Contraception: For participants of reproductive potential, willingness to use at least one highly effective method of contraception (e.g., intrauterine device, hormonal contraception, sterilization) or two effective methods (e.g., barrier method plus spermicide) during the study and for at least one month after the final esketamine dose. Contraceptive method(s) will be documented at baseline via self-report on a standardized form and reaffirmed at each esketamine session by research staff. Participants who become pregnant or are unable to confirm adequate contraception will be withdrawn from the study for safety reasons.\n* Availability: Willingness and ability to attend all scheduled sessions and complete study procedures.\n* Motivation for Engagement: Demonstrates willingness and psychological readiness to engage in guided reflective work before and after esketamine dosing (as assessed during clinical intake).\n\nExclusion Criteria:\n\n* Acute Suicide Risk: Immediate need for inpatient psychiatric hospitalization due to suicidal ideation with plan or intent as identified through the C-SSRS.\n* Psychotic or Bipolar Disorders: Current diagnosis of bipolar I disorder (manic phase), schizophrenia, schizoaffective disorder, or other primary psychotic disorders if stated by participants as a past diagnosis or identified during the SCID-5.\n* Substance Use Disorder: Active moderate to severe substance use disorder (except nicotine) in the past 6 months as self-identified by participant or during the SCID-5.\n* Cognitive\u002FDevelopmental Impairments: Intellectual disability, dementia, or other cognitive\u002Fdevelopmental disorders that impair ability to engage meaningfully in structured psychotherapeutic sessions such as preparation or integration, per clinician judgment.\n* Medical Contraindications: Any medical condition judged to pose undue risk during esketamine administration (e.g., aneurysmal vascular disease, arteriovenous malformation, history of intracerebral hemorrhage, or hypersensitivity to esketamine\u002Fketamine).\n* Pregnancy\u002FBreastfeeding: Current pregnancy or breastfeeding.\n* Ongoing Structured Psychotherapy Likely to Confound Outcomes: Participation in any formal psychotherapy within the past 3 months that involves structured, weekly sessions focused on behavioral change or emotional processing (e.g., CBT, ACT, psychodynamic therapy), unless the therapy was completed or stabilized at a low-intensity level for at least 8 weeks prior to enrollment.\n* Prior Non-Response to Esketamine: Six or more prior esketamine (≥56 mg) or IV ketamine sessions (0.4-0.7 mg\u002Fkg) without clinical response.\n* Recent Ketamine Use: Use of ketamine\u002Fesketamine in the past 12 weeks.\n* Inability to Consent: Any condition rendering the participant unable to provide informed consent.\n* Prior Enrollment: Previous participation in this study.",{"count":87,"type":21},20,[24],"This study will explore the effects of esketamine (Spravato®), an FDA-approved nasal spray, on adults diagnosed with treatment-resistant depression (TRD). All participants will receive esketamine as prescribed by a healthcare professional in a clinical setting.\n\nThe purpose of this research is to understand whether adding therapeutic support in the form of preparation and integration sessions - before and after the esketamine doses - can enhance the treatment experience and lead to longer-lasting improvements in mood and functioning.\n\nParticipants will be randomly assigned to one of two groups:\n\nEsketamine with therapeutic support sessions (integration group) Esketamine without additional support (standard care group) Both groups will receive standard monitoring and psychiatric evaluation during the study. The support sessions offered in the integration group are designed to help participants prepare for their treatment sessions and make sense of their experiences afterward, using a structured, evidence-based approach.\n\nThe study will last approximately 8 weeks per participant, with follow-up assessments. The goal is to learn whether integration therapy can improve treatment outcomes, safety, and satisfaction for individuals with depression that hasn't responded to other treatments.",[91],"Treatment-resistant Depression (TRD)",[93,94,95,96,97,98,99,100,101,102,103,104,105,106,107],"esketamine","Treatment-Resistant Depression","Spravato","Ketamine-Assisted Psychotherapy","Psychedelic Integration","Depression","Integration Therapy","Preparation and Integration","Mental Health","Dissociation","Intranasal Esketamine","Randomized Controlled Trial","Psychiatric Treatment","Therapeutic Support","Psychedelic Medicine","RECRUITING","2026-01-23",{"date":111,"type":39},"2026-01-27",{"date":113,"type":21},"2026-02-01",{"date":115,"type":21},"2026-12-01",{"name":45,"class":46},2,{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":124,"targetDuration":126,"studyType":127,"phases":4,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":140,"locationsCount":4},"100595962","food-allergy-registry-and-awareness-campaign-in-puerto-rico-100595962","NCT07039266","Food Allergy Registry and Awareness Campaign in Puerto Rico","Inclusion Criteria:\n\n* We will recruit Puerto Rican residents aged 0 -100 years diagnosed with food allergies by board-certified allergists. A food allergy diagnosis requires a positive prick skin test or specific IgE and a history of anaphylaxis or the development of cutaneous, respiratory, cardiovascular, or vomiting within 2 hours of ingestion or a positive food challenge.",{"count":125,"type":21},151,"1 Day","OBSERVATIONAL","Food Allergies affect 8% of children and 11% of adults, and there are increasing trends worldwide. Suffering food allergies reduces the quality of life and increases ED visits, hospitalizations, and mortality. Minorities in the United States suffer an increased food allergy burden, with higher prevalence, morbidity, and decreased use of preventive measures. Limited information is available in Puerto Rico. Moreover, advances in food allergy diagnostics, prevention, and treatment offer new hope for patients. We aim to develop a de-identified physician-diagnosed food allergy registry in Puerto Rico to characterize the food allergy population demographics, comorbidities, healthcare use, treatment, and quality of life. Our second aim is to educate patients with web-based posts to improve knowledge and awareness of food allergies.",[130],"Food Allergy Proved",[132,133],"Food Allergy","Allergy","2025-06-18",{"date":136,"type":39},"2025-06-26",{"date":138,"type":21},"2025-07-01",{"date":115,"type":21},{"name":45,"class":46},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":4,"eligibilityCriteria":146,"healthyVolunteers":147,"sex":16,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":117},"100593761","a-comparison-of-video-versus-written-instructions-for-early-motion-flexors-rehabilitation-100593761","NCT07010640","A Comparison of Video Versus Written Instructions for Early Motion Flexors Rehabilitation","Inclusion Criteria:\n\nPatients 18 years old or older Isolated flexor injuries Procedures performed under WALANT technique Providing written informed consent\n\nExclusion Criteria:\n\nPatients younger than 18 years old Patients with other injuries Procedures performed under any anesthesia other than WALANT Mental disability History of psychiatric disorders",true,"18 Years",{"count":150,"type":21},60,[58],"The research objective is to evaluate the efficacy of video instructions compared to written or verbal instructions for early motion rehabilitation following hand flexor repair. The primary research question addresses whether video instructions improve compliance with early motion rehabilitation post-surgery compared to traditional methods. The hypothesis is that patients who receive video instructions are more likely to adhere to their rehabilitation regimen than those who receive verbal or written instructions.",[154,155,156],"Compliance, Treatment","Hand Flexor Repair","Compliance to Rehabilitation After Hand Flexor Repair","2025-05-29",{"date":159,"type":39},"2025-06-08",{"date":161,"type":21},"2025-08",{"date":163,"type":21},"2026-07-15",{"name":45,"class":46},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":147,"sex":172,"minAge":17,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":22,"phases":176,"briefSummary":177,"conditions":178,"keywords":4,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":47},"100501069","optimizing-pre-exposure-prophylaxis-prep-among-latino-men-who-have-sex-with-men-msm-in-puerto-rico-100501069","NCT05804461","Optimizing Pre-Exposure Prophylaxis (PrEP) Among Latino Men Who Have Sex With Men (MSM) in Puerto Rico","Optimizing PrEP Uptake Among Latino MSM in Puerto Rico: A Comparative Effectiveness Study","Latino MSM group - Inclusion Criteria:\n\n* Biological male\n* Age 21 or older\n* Self-reported HIV negative or unknown status\n* Not using PrEP (participants who have discontinued PrEP use can participate in the study), Spanish fluency (ability to write and read in Spanish)\n* Presenting at least one of the eligibility criteria for PrEP as established by the CDC (including men who have had an infection (STI) in the past 6 months, HIV positive sexual partner)\n* Access to a portable technology device (e.g., phone, tablet, laptop) or desktop computer access to internet connection\n\nExclusion Criteria:\n\n* HIV positive individual\n* Evidence of being under the effects of alcohol or drugs\n* Indication of unstable or serious psychiatric symptoms\n* Evidence of major cognitive impairment\n* Inability to speak and read in Spanish\n\nHealthcare Providers group - Inclusion Criteria:\n\n* Age 21 or older\n* Providing PrEP related health services at time of enrollment (e.g., case management, clinical services)\n* Spanish fluency (ability to write and read in Spanish)\n\nExclusion Criteria:\n\n* Evidence of being under the effects of alcohol or drugs\n* Indication of unstable or serious psychiatric symptoms\n* Evidence of major cognitive impairment\n* Inability to speak and read in Spanish","MALE","99 Years",{"count":175,"type":21},182,[58],"To develop, assess and compare the effectiveness of a Motivational Interviewing Intervention for increasing Pre-Exposure Prophylaxis (PrEP) uptake among Latino Men Who Have Sex With Men (MSM) in Puerto Rico.",[179],"HIV Prevention",{"date":181,"type":39},"2025-05-30",{"date":183,"type":39},"2023-09-01",{"date":185,"type":21},"2026-05-31",{"name":45,"class":46},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":47},"100586572","multimodal-pain-management-after-wide-awake-local-anesthesia-no-tourniquet-orthopedic-hand-surgery-a-randomized-control-trial-100586572","NCT06917118","Multimodal Pain Management After Wide Awake Local Anesthesia No Tourniquet Orthopedic Hand Surgery: A Randomized Control Trial","WALANT","Inclusion Criteria:\n\n* Patients 21-70 years of age undergoing outpatient hand surgery\n* Patients undergoing surgery with WALANT technique\n* Patients who provide written informed consent\n\nExclusion Criteria:\n\n* Patients aged 20 and younger, or 71 and older\n* Patient with chronic pain requiring opioid use\n* Pregnant patients\n* Patients who do not self-identify as Hispanic\n* Patients with known allergy to the medication\n* Patients with contraindications for the prescribed medications","70 Years",{"count":196,"type":21},100,[58],"The main objective of the study is to measure the efficacy of a multimodal postoperative pain regimen consisting of oral acetaminophen and naproxen compared to a traditional opioid-only pain regimen following elective wide awake local anesthesia no tourniquet (WALANT) hand surgery in a Hispanic population. The study is a randomized control trial comparing the clinical outcomes of patients undergoing elective WALANT hand surgery performed by a board-certified, fellowship-trained orthopedic hand surgeon (Dr. Christian A. Foy).\n\nThe study groups are:\n\n* Control group: standard pain control with opioids\n* Experimental group: multimodal non-opioid pain control\n\nStudy Outcomes are:\n\n* VAS pain scores (7 days),\n* Total opioid usage\n* Patient satisfaction\n* Adverse events\n\nWe hypothesize that patients receiving multimodal pain regimens will report lower opioid use, lower pain scores, and greater satisfaction than patients receiving traditional opioid-only pain management.",[200],"Pain Management",[192,202,203,204],"Multimodal analgesia","Nonopioid pain management","VAS pain scores","2025-03-31",{"date":207,"type":39},"2025-04-08",{"date":209,"type":21},"2025-05-01",{"date":211,"type":21},"2025-12-01",{"name":45,"class":46},{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":220,"minAge":17,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":108,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":238,"locationsCount":47},"100581071","phase-1-oral-metformin-for-treating-melasma-in-latin-american-women-100581071","NCT06845540","Oral Metformin for Treating Melasma in Latin American Women","Oral Metformin in the Treatment of Melasma: a Prospective Trial in Latin American Women","Inclusion Criteria: Latin American women aged 21 years or older, diagnosed epidermal or mixed melasma\n\nExclusion Criteria: pregnancy, breastfeeding, use of hydroquinone or tretinoin within 2 months before the study, or undergoing laser treatment, peels, microdermabrasion, or microneedling within 2 months of the study. Patients with a history of renal or liver disease, metformin allergy, diabetes, hypoglycemia, or those on medications that could interact with metformin will also be excluded.","FEMALE",{"count":222,"type":21},30,[224,225],"PHASE1","PHASE2","The goal of this clinical trial is to learn if metformin can treat melasma in Latin American women. The main question it aims to answer is:\n\n\\- Can metformin help reduce the dark patches of melasma?\n\nResearchers will test two different doses of metformin (500 mg and 1000 mg) to see if either one helps improve melasma.\n\nParticipants will:\n\n* Take a metformin pill every day for three months.\n* Go to the clinic twice: once at the beginning and once at the end of the study.\n* Get a phone call from the researchers to check how they're doing and ask about any changes or side effects.",[228],"Melasma",[230,231],"melasma","metformin","2025-02-19",{"date":234,"type":39},"2025-02-25",{"date":236,"type":21},"2025-02-20",{"date":181,"type":21},{"name":45,"class":46},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":257,"locationsCount":4},"100554254","impact-of-suture-technique-on-wound-healing-in-ankle-fracture-surgery-a-randomized-controlled-trial-100554254","NCT06496698","Impact of Suture Technique on Wound Healing in Ankle Fracture Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients aged 21 years or older with isolated ankle fractures requiring surgical intervention and who consent to participate.\n\nExclusion Criteria:\n\n* Patients that will be excluded from this study include those with complex ankle fractures, open fractures, a history of wound healing disorders, and\u002For those unable to provide consent.",{"count":246,"type":21},80,[58],"Our primary aim is to compare the complication rates of patients with ankle fractures who underwent skin closure using a running subcuticular suture pattern compared to an interrupted suture pattern. At the time of the operation, participants will be assigned to either the Subcuticular Suture Group (SSG) or the Simple Interrupted Suture Group (SISG) using computer-generated randomization programs. The surgeon will perform the assigned closure technique using standardized techniques. Running subcuticular Vicryl 3-0 sutures will be placed on patients in the experimental group while simple interrupted Monocryl 3-0 sutures patients in our control group.\n\nPatients will be followed up at the two-week and eight-week postoperative mark where we will use the Patient and Observer Scar Assessment Scale (POSAS) to evaluate and compare wound healing. Additionally, photographs of the scars will be captured to visually assess the healing progression.",[250],"Ankle Fractures","2024-07-03",{"date":253,"type":39},"2024-07-11",{"date":255,"type":21},"2024-07-15",{"date":163,"type":21},{"name":45,"class":46},{"id":259,"slug":260,"hasResults":11,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":147,"sex":16,"minAge":17,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":274,"leadSponsor":276,"locationsCount":47},"100553172","the-effect-of-the-transection-of-the-omohyoid-in-the-incidence-of-dysphagia-in-patients-100553172","NCT06482632","The Effect of the Transection of the Omohyoid in the Incidence of Dysphagia in Patients","The Effect of the Transection of the Omohyoid in the Incidence of Dysphagia in Patients Undergoing Multilevel Anterior Cervical Discectomy and Fusion","Inclusion Criteria:\n\n* The target population is female and male patients between 21 - 85 years old undergoing multilevel anterior cervical decompression and fusion.\n\nExclusion Criteria:\n\n* Patients with a history of preoperative dysphagia, those with conditions that expose them to high risk of postoperative dysphagia (such as motor neuron disease), and those with cervical non-degenerative pathology, such as tumor or trauma as well as those who have lost to follow up, will be excluded from the study.","85 Years",{"count":150,"type":21},[58],"The investigators believe that the transection of the omohyoid during an anterior cervical discectomy and fusion decreases the incidence of dysphagia in patients who undergo this procedure when compared to patients who do not have the omohyoid transected.",[270],"Anterior Cervical Pain",{"date":272,"type":39},"2024-07-08",{"date":255,"type":21},{"date":275,"type":21},"2026-05-29",{"name":45,"class":46},""]